Real-World Study Confirms Baricitinib's Effectiveness for Alopecia Areata

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-15 16:00 GMT | Update On 2025-08-16 06:49 GMT

A recent real-world study conducted in China has confirmed that baricitinib, a Janus kinase (JAK) inhibitor, significantly improves hair regrowth in patients with various forms of alopecia areata, including totalis, universalis, and eyebrow/eyelash loss.

The study observed a substantial reduction in the Severity of Alopecia Tool (SALT) scores, with an average improvement from 70.21 at baseline to 48.51 after treatment. A total of 47 patients met inclusion criteria. At weeks 12 and 24, 47% and 53% achieved SALT 20, respectively. By the end of treatment (24–104 months), 78.7% achieved SALT 20.

The overall SALT score improvement before and after treatment was 48.51 (±30.36), with a hair regrowth rate of 68.10% ± 35.45%. Patients with disease duration ≤ 4 years showed significantly greater SALT score improvement and shorter time to hair regrowth onset compared to those with > 4 years.

At week 24, 85.2% and 90.4% achieved ClinRO scores of 0/1 for eyebrow and eyelash alopecia, respectively. Negative correlations were observed between disease duration and hair regrowth rate, a positive correlation was found between treatment duration and hair regrowth rate. Baricitinib was well tolerated with no serious adverse events. These findings align with previous research supporting baricitinib's efficacy and safety in treating severe alopecia areata.

The study's results suggest that baricitinib is a promising treatment option for patients with various forms of alopecia areata, offering significant improvements in hair regrowth without serious side effects.

Reference:

Wada-Irimada, M., Takahashi, T., Sekine, M., et al. (2025). Long-term real-world outcomes of baricitinib in severe alopecia areata: A 104-week retrospective analysis from a single institute. Journal of Dermatology. https://doi.org/10.1111/1346-8138.17829

Article Source : Dermatologic Therapy

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Real-World Study Confirms Baricitinib's Effectiveness for Alopecia Areata

Similar News

Global Study Finds Nearly 1 Percent of Population Affected by Hidradenitis Suppurativa

Elevated serum vitamin D levels are linked with higher skin cancer risk, finds study

Alopecia Areata Linked to Autoimmune Thyroid Diseases, Suggests Study

Infection Risk among HS Patients Compared to Psoriasis: JAMA

Roflumilast Cream 0.3% Safe and Effective for Plaque Psoriasis in Children Aged 2-11 Years: Study

Study Finds No Clear Link Between Vitiligo and Cancer Risk

Novel dietary Supplement AGA-P Enhances Effectiveness of Parmacological Treatments for Androgenic Alopecia: Study

Bullous Pemphigoid Patients Face Higher Risk of Osteoporosis and Hip Fractures: Study Suggests